Trial Profile
A phase II, eight week, multi-center, open label trial of Xyrem (sodium oxybate) for excessive daytime sleepiness and nocturnal sleep disturbance in patients with mild to moderate Parkinson's disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Parkinson's disease; Sleep disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms Xyrem
- 17 Apr 2008 New trial record.